FOLH1 and neoplasm: First PSMA-based PET studies in patients with brain tumours have shown generally comparable, but moderate uptake of various radioligands at the tumour site.4, 5, 6, 7 The first reports on PSMA-based RLT for patients with malignant brain tumours showed little side-effects, however, no improvement of survival has been documented yet; likely because of the observed limited tumour uptake following intravenous (IV) administration.6